BioCentury
ARTICLE | Company News

Senz debuts with seed financing

August 23, 2012 12:01 AM UTC

Senz Oncology Pty. Ltd. (Melbourne, Australia) made its public debut Wednesday with a seed investment from CoValence. Senz would not disclose the amount. Senz plans to start a Phase I/II trial before year end of VAL-1000, an oral chemotherapeutic agent, to treat acute myelogenous leukemia (AML). VAL-1000 targets several cellular kinases, including cyclin dependent kinases (CDKs). Senz is co-developing the product with Allyence Research Inc. (Menlo Park, Calif.). ...